PE20142402A1 - Sintesis de compuestos de ester y acido borico - Google Patents

Sintesis de compuestos de ester y acido borico

Info

Publication number
PE20142402A1
PE20142402A1 PE2014001477A PE2014001477A PE20142402A1 PE 20142402 A1 PE20142402 A1 PE 20142402A1 PE 2014001477 A PE2014001477 A PE 2014001477A PE 2014001477 A PE2014001477 A PE 2014001477A PE 20142402 A1 PE20142402 A1 PE 20142402A1
Authority
PE
Peru
Prior art keywords
synthesis
ester
boric acid
acid compounds
halogen
Prior art date
Application number
PE2014001477A
Other languages
English (en)
Inventor
Vince Ammoscato
John E Bishop
Fang-Ting Chiu
Achim Geiser
Jean-Marc Gomez
Robert Hett
Christoph Koellner
Vithalanand R Kulkarni
Young Lo
Steven Munk
Iain Fraser Pickersgill
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34968044&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20142402(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Publication of PE20142402A1 publication Critical patent/PE20142402A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/04—Esters of boric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Catalysts (AREA)

Abstract

SE REFIERE A UN PROCESO PARA PREPARAR UN COMPUESTO DE ESTER BORICO DE FORMULA(I): DONDE R1 ES UN GRUPO ALIFATICO C1-C8, ARILO C6-C10, ENTRE OTROS; R2 ES HIDROGENO O HALOGENO; R3 ES HALOGENO Y CADA R4 Y R5, ES INDEPENDIENTEMENTE, ES UN GRUPO ALIFATICO C1-C12, AROMATICO C6-C14, ENTRE OTROS. DICHO PROCESO OFRECE UN MAYOR RENDIMIENTO.
PE2014001477A 2004-03-30 2005-03-29 Sintesis de compuestos de ester y acido borico PE20142402A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US55753504P 2004-03-30 2004-03-30

Publications (1)

Publication Number Publication Date
PE20142402A1 true PE20142402A1 (es) 2015-02-04

Family

ID=34968044

Family Applications (3)

Application Number Title Priority Date Filing Date
PE2005000359A PE20060162A1 (es) 2004-03-30 2005-03-29 Sintesis de compuestos de ester y acido borico
PE2014001477A PE20142402A1 (es) 2004-03-30 2005-03-29 Sintesis de compuestos de ester y acido borico
PE2009001314A PE20110075A1 (es) 2004-03-30 2005-03-29 Sintesis de compuestos de ester borico

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PE2005000359A PE20060162A1 (es) 2004-03-30 2005-03-29 Sintesis de compuestos de ester y acido borico

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2009001314A PE20110075A1 (es) 2004-03-30 2005-03-29 Sintesis de compuestos de ester borico

Country Status (41)

Country Link
US (14) US7714159B2 (es)
EP (5) EP2377869B1 (es)
JP (4) JP4558039B2 (es)
KR (1) KR100939598B1 (es)
CN (5) CN111925385B (es)
AR (3) AR049374A1 (es)
AT (1) ATE521612T1 (es)
AU (1) AU2005230930B2 (es)
BR (1) BRPI0509587A (es)
CA (4) CA2853272A1 (es)
CL (2) CL2010000350A1 (es)
CR (1) CR8653A (es)
CY (3) CY1112053T1 (es)
DK (4) DK1756121T3 (es)
DO (1) DOP2011000293A (es)
EA (1) EA012927B1 (es)
EC (1) ECSP066960A (es)
ES (4) ES2899606T3 (es)
FI (1) FI4008721T3 (es)
HK (1) HK1246300A1 (es)
HR (4) HRP20110846T1 (es)
HU (2) HUE065769T2 (es)
IL (3) IL178250A (es)
LT (2) LT4008721T (es)
ME (1) ME01975B (es)
MX (1) MX367324B (es)
MY (1) MY145427A (es)
NL (3) NL1028639C2 (es)
NO (4) NO338905B1 (es)
NZ (3) NZ598172A (es)
PE (3) PE20060162A1 (es)
PL (4) PL2377869T3 (es)
PT (4) PT3385267T (es)
RS (4) RS53259B (es)
SG (5) SG10201600029PA (es)
SI (4) SI3385267T1 (es)
TW (1) TWI386212B (es)
UA (1) UA90108C2 (es)
UY (3) UY28830A1 (es)
WO (1) WO2005097809A2 (es)
ZA (1) ZA200608689B (es)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6083903A (en) * 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
ES2899606T3 (es) 2004-03-30 2022-03-14 Millennium Pharm Inc Síntesis de compuestos de ésteres y ácidos borónicos
WO2008075376A1 (en) * 2006-12-18 2008-06-26 Natco Pharma Limited Polymorphic forms of bortezomib and process for their preparation
WO2009004350A1 (en) * 2007-07-03 2009-01-08 Pliva Hrvatska D.O.O. Methods for preparing bortezomib and intermediates used in its manufacture
KR20140042933A (ko) * 2007-08-06 2014-04-07 밀레니엄 파머슈티컬스 인코퍼레이티드 프로테아좀 억제제
US7442830B1 (en) 2007-08-06 2008-10-28 Millenium Pharmaceuticals, Inc. Proteasome inhibitors
AU2016253697A1 (en) * 2007-08-06 2016-11-24 Millennium Pharmaceuticals, Inc. Proteasome inhibitors
EA034601B1 (ru) * 2007-08-06 2020-02-25 Милленниум Фармасьютикалз, Инк. Способ получения бороновых кислот
US20110118274A1 (en) * 2007-08-23 2011-05-19 Cornell Research Foundation, Inc. Proteasome inhibitors and their use in treating pathogen infection and cancer
BRPI0816807A2 (pt) * 2007-09-12 2017-05-16 Dr Reddy's Laboratories Inc bortezomib e processo para a produção do mesmo
US7838673B2 (en) 2007-10-16 2010-11-23 Millennium Pharmaceuticals, Inc. Proteasome inhibitors
SI2318419T2 (sl) 2008-06-17 2025-10-30 Takeda Pharmaceutical Company Limited Spojine boronat estra in njihovi farmacevtski sestavki
AU2013204896A1 (en) * 2008-09-29 2013-05-16 Millennium Pharmaceuticals, Inc. Derivatives of 1-amino-2-cyclobutylethylboronic acid
AR075090A1 (es) 2008-09-29 2011-03-09 Millennium Pharm Inc Derivados de acido 1-amino-2-ciclobutiletilboronico inhibidores de proteosoma,utiles como agentes anticancerigenos, y composiciones farmaceuticas que los comprenden.
EP2238973A1 (en) 2009-04-07 2010-10-13 Cephalon France Lyophilized preparations of proteasome inhibitors
CN101899062B (zh) * 2009-05-26 2015-04-15 上海威智医药科技有限公司 α-手性硼酸及硼酸酯的合成工艺
JP2012530116A (ja) 2009-06-19 2012-11-29 レツク・フアーマシユーテイカルズ・デー・デー 脱ハロゲン化なしにハロゲノアルケンを水素化する方法
EP2270019A1 (en) 2009-06-19 2011-01-05 LEK Pharmaceuticals d.d. New synthetic route for the preparation of alpha-amino boronic esters
EP2280016A1 (en) 2009-07-27 2011-02-02 LEK Pharmaceuticals d.d. New synthetic route for the preparation of alpha-amino boronic esters via substituted alk-1-ynes
NZ600786A (en) 2009-12-22 2013-12-20 Cephalon Inc Proteasome inhibitors and processes for their preparation, purification and use
WO2011090940A1 (en) 2010-01-19 2011-07-28 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutic delivery
WO2011098963A1 (en) 2010-02-09 2011-08-18 Ranbaxy Laboratories Limited Process for the preparation of bortezomib
CN101781326B (zh) * 2010-02-11 2013-08-21 福建南方制药股份有限公司 一种制备手性氨基硼酸的中间体及其制备方法
WO2011107912A1 (en) 2010-03-04 2011-09-09 Ranbaxy Laboratories Limited Polymorphic forms of bortezomib
RU2529800C2 (ru) * 2010-03-18 2014-09-27 ИННОФАРМА, Инк. Стабильные составы бортезомиба
US8263578B2 (en) 2010-03-18 2012-09-11 Innopharma, Inc. Stable bortezomib formulations
AU2011235227B2 (en) 2010-03-31 2016-09-08 Millennium Pharmaceuticals, Inc. Derivatives of 1-amino-2-cyclopropylethylboronic acid
CN101812026B (zh) * 2010-04-12 2013-08-28 亚邦医药股份有限公司 一种硼替佐米的合成方法
CA2927832C (en) 2010-05-18 2021-03-23 Cerulean Pharma Inc. Cyclodextrin-containing polymer-therapeutic agent conjugates and their use
ES2548256T3 (es) 2010-10-14 2015-10-15 Synthon Bv Proceso para la preparación de bortezomib y los intermedios para el proceso
TW201309303A (zh) 2011-03-03 2013-03-01 Cephalon Inc 用於治療狼瘡的蛋白酶體抑制劑
CN102206188B (zh) * 2011-04-08 2013-02-27 苏州二叶制药有限公司 N-(吡嗪-2-基羰基)-l-苯丙氨酸的制备方法
US8497374B2 (en) 2011-05-12 2013-07-30 Scinopharm Taiwan, Ltd. Process for preparing and purifying bortezomib
CN102268029B (zh) * 2011-05-19 2013-10-09 苏州二叶制药有限公司 化合物（1s,2s,3r,5s）-蒎烷二醇-l-苯丙氨酸-l-亮氨酸硼酸酯的制备
WO2012177835A1 (en) 2011-06-22 2012-12-27 Cephalon, Inc. Proteasome inhibitors and processes for their preparation, purification and use
CN102351890B (zh) * 2011-09-30 2014-07-02 重庆泰濠制药有限公司 一种硼替佐米的合成方法
CN102492021B (zh) * 2011-12-13 2013-10-23 重庆泰濠制药有限公司 硼替佐米的制备工艺
SG10201605152SA (en) 2011-12-22 2016-08-30 Ares Trading Sa Alpha-amino boronic acid derivatives, selective immunoproteasome inhibitors
CN103374026A (zh) * 2012-04-27 2013-10-30 重庆医药工业研究院有限责任公司 一种硼替佐米中间体的制备方法
CN103450331B (zh) * 2012-06-05 2016-05-25 山东新时代药业有限公司 一种硼替佐米的精制方法
CA2884292A1 (en) * 2012-09-11 2014-03-20 Cipla Limited Process for preparing of bortezomib
WO2014072985A1 (en) 2012-11-06 2014-05-15 Natco Pharma Limited Novel boronic acid derivatives as anti cancer agents
EP2919786A4 (en) 2012-11-16 2016-06-01 Shilpa Medicare Ltd Crystalline bortezomib process
JP6403219B2 (ja) 2012-12-07 2018-10-10 ベナトルクス ファーマシューティカルズ，インク． ベータ−ラクタマーゼ阻害剤
CN103897026A (zh) * 2012-12-29 2014-07-02 朱继东 硼替佐米关键中间体的晶型，制备方法及其运用
CN103897027A (zh) * 2012-12-29 2014-07-02 曹亚英 关键中间体晶型，制备方法及其在硼替佐米合成中的运用
CN105101970B (zh) 2013-01-10 2018-11-20 维纳拓尔斯制药公司 β-内酰胺酶抑制剂
US10023611B2 (en) 2013-04-16 2018-07-17 Cipla Limited Process for the preparation of bortezomib mannitol ester
CN104211758B (zh) * 2013-05-29 2020-06-12 深圳翰宇药业股份有限公司 一种硼替佐米的制备方法
CN103497233B (zh) * 2013-09-30 2015-04-08 哈药集团技术中心 一种硼替佐米的制备方法
CN103554219A (zh) * 2013-10-01 2014-02-05 昆明贵研药业有限公司 一种制备硼替佐米的方法
KR101691353B1 (ko) * 2013-12-09 2016-12-30 주식회사 경보제약 보르테조밉의 제조방법 및 그의 신규 중간체
CN106132970B (zh) 2014-02-03 2020-09-04 俄亥俄州创新基金会 硼酸酯和其药物制剂
UA121389C2 (uk) 2014-05-20 2020-05-25 Мілленніум Фармасьютікалз, Інк. Борвмісні інгібітори протеасом для застосування після первинної протиракової терапії
KR102396753B1 (ko) 2014-06-11 2022-05-12 베나토알엑스 파마슈티컬스, 인크. 베타-락타마제 억제제
JP6420629B2 (ja) * 2014-10-30 2018-11-07 ボーグワーナー インコーポレーテッド チェーンガイドおよびチェーンテンショナアーム
DE102015204151B4 (de) * 2015-03-09 2025-12-24 Adidas Ag Ball, insbesondere Fußball, und Verfahren zur Herstellung eines Balls
JP6223508B2 (ja) * 2016-06-27 2017-11-01 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． プロテアソーム阻害剤
EP3494121B1 (en) 2016-08-04 2021-10-06 Venatorx Pharmaceuticals, Inc. Boron-containing compounds
EP3583110A1 (en) 2017-02-17 2019-12-25 Fresenius Kabi Oncology Ltd An improved process for the preparation of boronic acid esters
PH12019502037B1 (en) 2017-03-06 2024-06-05 Everest Medicines Singapore Pte Ltd Solid forms and combination compositions comprising a beta-lactamase inhibitor and uses thereof
EP3630782A4 (en) 2017-05-26 2021-03-03 Venatorx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
US11267826B2 (en) 2017-05-26 2022-03-08 VenatoRx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
CN109305980B (zh) 2017-07-28 2022-10-11 成都奥璟生物科技有限公司 一种硼酸酯化合物、其合成方法及其用途
EP3676272A4 (en) * 2017-09-02 2021-04-21 Sun Pharmaceutical Industries Limited IXAZOMIB CITRATE PREPARATION PROCESS
US12173018B2 (en) 2018-05-25 2024-12-24 VenatoRx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
CN111187336B (zh) * 2018-11-14 2022-05-20 正大天晴药业集团股份有限公司 硼替佐米的精制方法
DK3886798T3 (da) 2018-11-29 2026-04-20 Basilea Pharmaceutica Int Ag Allschwil Kombinationssammensætninger, som omfatter en beta-lactamase-hæmmer, og anvendelser deraf
US11964993B2 (en) 2021-07-03 2024-04-23 Shilpa Pharma Lifesciences Limited Crystalline bortezomib process
US20250059215A1 (en) 2023-08-07 2025-02-20 Tae Life Sciences Llc Trifluoroborate (BF3) Compositions For Use In Boron Neutron Capture Therapy and Methods Thereof
EP4791750A1 (en) * 2023-10-13 2026-08-19 The Brigham & Women's Hospital, Inc. Proteasome inhibitors and methods of use thereof
CN120248757A (zh) * 2025-05-28 2025-07-04 滁州瑞达新能源材料有限公司 一种自清洁耐候的铝合金光伏组件边框及其制备方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL31992A (en) * 1968-05-08 1973-07-30 American Cyanamid Co Synthetic thyrocalcitonins and method of making them
ZA794723B (en) * 1978-09-11 1980-08-27 Univ Miami Anti-hypertensive agents
US4525309A (en) * 1983-03-15 1985-06-25 Washington State University Research Foundation, Inc. Lewis acid catalysis of the homologation of boronic esters with haloalkylmetal reagents
US4499082A (en) 1983-12-05 1985-02-12 E. I. Du Pont De Nemours And Company α-Aminoboronic acid peptides
US4537773A (en) 1983-12-05 1985-08-27 E. I. Du Pont De Nemours And Company α-Aminoboronic acid derivatives
ES542440A0 (es) * 1985-04-22 1985-12-16 Inke Sa "procedimiento para la obtencion del ester benzilico de 1-(n-(1--etoxicarbonil-3-oxo-fenilpropil)-l-alanil)-l-prolina".
SE8506094D0 (sv) * 1985-12-20 1985-12-20 Astra Laekemedel Ab New antibacterial agents and intermediates therefor
US4701545A (en) * 1986-02-12 1987-10-20 Washington State University Research Foundation, Inc. Preparation of α,α-dihaloalkyl boronic esters
US5250720A (en) 1987-06-05 1993-10-05 The Dupont Merck Pharmaceutical Company Intermediates for preparing peptide boronic acid inhibitors of trypsin-like proteases
US5242904A (en) 1987-06-05 1993-09-07 The Dupont Merck Pharmaceutical Company Peptide boronic acid inhibitors of trypsin-like proteases
US5187157A (en) * 1987-06-05 1993-02-16 Du Pont Merck Pharmaceutical Company Peptide boronic acid inhibitors of trypsin-like proteases
EP0315574A3 (de) 1987-11-05 1990-08-22 Hoechst Aktiengesellschaft Renin-Inhibitoren
US5106948A (en) 1988-05-27 1992-04-21 Mao Foundation For Medical Education And Research Cytotoxic boronic acid peptide analogs
US6083903A (en) 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
CA2435146C (en) * 2001-01-25 2011-03-29 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Formulation of boronic acid compounds
WO2003033506A1 (en) * 2001-10-12 2003-04-24 Kyorin Pharmaceutical Co., Ltd. Aminoborane acid derivative and proteasome inhibitory drug containing the same
WO2003033507A1 (en) * 2001-10-12 2003-04-24 Kyorin Pharmaceutical Co., Ltd. Benzylmalonic acid derivatives and proteasome inhibitors contaiing the same
ES2899606T3 (es) * 2004-03-30 2022-03-14 Millennium Pharm Inc Síntesis de compuestos de ésteres y ácidos borónicos
WO2009004350A1 (en) * 2007-07-03 2009-01-08 Pliva Hrvatska D.O.O. Methods for preparing bortezomib and intermediates used in its manufacture
US7838673B2 (en) * 2007-10-16 2010-11-23 Millennium Pharmaceuticals, Inc. Proteasome inhibitors
JP2012530116A (ja) * 2009-06-19 2012-11-29 レツク・フアーマシユーテイカルズ・デー・デー 脱ハロゲン化なしにハロゲノアルケンを水素化する方法

Also Published As

Publication number Publication date
US20210395301A1 (en) 2021-12-23
PT1756121E (pt) 2011-11-30
ZA200608689B (en) 2007-09-26
US20200369722A1 (en) 2020-11-26
SI1756121T1 (sl) 2012-03-30
IL178250A0 (en) 2006-12-31
RS51983B (sr) 2012-02-29
US20130005968A1 (en) 2013-01-03
CY1124753T1 (el) 2022-07-22
US20180044377A1 (en) 2018-02-15
EP2377868A1 (en) 2011-10-19
US20100174072A1 (en) 2010-07-08
ES2371652T3 (es) 2012-01-05
NL1033190C2 (nl) 2007-11-27
JP5894952B2 (ja) 2016-03-30
RS65253B1 (sr) 2024-03-29
NZ598172A (en) 2013-08-30
CL2014002252A1 (es) 2014-12-05
US20180265546A1 (en) 2018-09-20
AU2005230930B2 (en) 2011-09-29
SG182998A1 (en) 2012-08-30
NO344610B1 (no) 2020-02-10
JP2010241816A (ja) 2010-10-28
US20210171574A1 (en) 2021-06-10
NZ586824A (en) 2012-03-30
HRP20212002T1 (hr) 2022-04-01
ME01975B (me) 2015-05-20
CN1960996A (zh) 2007-05-09
WO2005097809A2 (en) 2005-10-20
AR097309A2 (es) 2016-03-02
IL219856A0 (en) 2012-06-28
BRPI0509587A (pt) 2007-09-25
ECSP066960A (es) 2006-12-20
SI4008721T1 (sl) 2024-05-31
CA2738706C (en) 2014-10-14
SG10201600029PA (en) 2016-02-26
JP2007530687A (ja) 2007-11-01
LT3385267T (lt) 2021-11-10
CA2859119A1 (en) 2005-10-20
MY145427A (en) 2012-02-15
KR20070007873A (ko) 2007-01-16
CA2560886C (en) 2014-08-12
RS53259B (sr) 2014-08-29
DK3385267T3 (da) 2021-11-01
SG151322A1 (en) 2009-04-30
SI3385267T1 (sl) 2022-04-29
US20160362449A1 (en) 2016-12-15
NO20064893L (no) 2006-12-22
PT4008721T (pt) 2024-03-21
EA012927B1 (ru) 2010-02-26
SG182999A1 (en) 2012-08-30
PL4008721T3 (pl) 2024-05-13
CN111925385A (zh) 2020-11-13
DK4008721T3 (da) 2024-03-25
JP6193960B2 (ja) 2017-09-06
SI2377869T1 (sl) 2014-05-30
EP2377869A1 (en) 2011-10-19
HUE056859T2 (hu) 2022-03-28
CY1112053T1 (el) 2015-11-04
CN111925385B (zh) 2023-11-21
CR8653A (es) 2007-10-23
IL178250A (en) 2012-06-28
US20050240047A1 (en) 2005-10-27
HRP20240307T3 (hr) 2024-05-10
CN108329337A (zh) 2018-07-27
PT3385267T (pt) 2021-11-23
NL1033190A1 (nl) 2007-04-23
HK1246300A1 (zh) 2018-09-07
CN103396427B (zh) 2018-04-13
US9862745B2 (en) 2018-01-09
NL1028639C2 (nl) 2007-01-17
CN1960996B (zh) 2016-04-20
ATE521612T1 (de) 2011-09-15
US20220204558A1 (en) 2022-06-30
DK1756121T3 (da) 2012-01-09
UY35578A (es) 2016-01-08
NL1033189C2 (nl) 2008-08-14
NL1028639A1 (nl) 2005-10-20
DK2377869T3 (da) 2014-04-14
NZ550522A (en) 2010-08-27
TWI386212B (zh) 2013-02-21
CA2738706A1 (en) 2005-10-20
UA90108C2 (uk) 2010-04-12
EP4008721A1 (en) 2022-06-08
HK1100004A1 (en) 2007-08-31
US20190330270A1 (en) 2019-10-31
PL3385267T3 (pl) 2022-02-14
CY1115336T1 (el) 2017-01-04
PT2377869E (pt) 2014-04-15
US10000529B2 (en) 2018-06-19
HUE065769T2 (hu) 2024-06-28
DOP2011000293A (es) 2011-12-15
IL219853A0 (en) 2012-06-28
EP1756121B1 (en) 2011-08-24
TW200616646A (en) 2006-06-01
MX367324B (es) 2019-08-15
IL219856A (en) 2015-05-31
CN108329337B (zh) 2021-06-25
KR100939598B1 (ko) 2010-02-01
CA2853272A1 (en) 2005-10-20
CN103396427A (zh) 2013-11-20
JP4558039B2 (ja) 2010-10-06
JP2016056180A (ja) 2016-04-21
AR049374A1 (es) 2006-07-26
NO338905B1 (no) 2016-10-31
NO20171939A1 (no) 2006-12-22
HK1257298A1 (zh) 2019-10-18
HRP20140339T1 (hr) 2014-05-09
EP1756121A2 (en) 2007-02-28
PE20060162A1 (es) 2006-04-07
JP5414625B2 (ja) 2014-02-12
US20150038706A1 (en) 2015-02-05
ES2899606T3 (es) 2022-03-14
CL2010000350A1 (es) 2011-01-28
UY28830A1 (es) 2005-09-30
US20200157143A1 (en) 2020-05-21
HK1164320A1 (en) 2012-10-19
PL2377869T3 (pl) 2014-07-31
UY34969A (es) 2015-02-27
FI4008721T3 (fi) 2024-03-19
ES2974758T3 (es) 2024-07-01
NO343966B1 (no) 2019-07-29
NL1033189A1 (nl) 2007-10-22
AR097310A2 (es) 2016-03-02
CA2560886A1 (en) 2005-10-20
RS62738B1 (sr) 2022-01-31
ES2457593T3 (es) 2014-04-28
US7714159B2 (en) 2010-05-11
EP4008721B1 (en) 2024-01-03
CN107474062A (zh) 2017-12-15
JP2013100378A (ja) 2013-05-23
EA200601795A1 (ru) 2007-04-27
NO20161350A1 (no) 2006-12-22
AU2005230930A1 (en) 2005-10-20
NO20191065A1 (no) 2006-12-22
LT4008721T (lt) 2024-03-25
EP2377869B1 (en) 2014-01-29
SG10201800972PA (en) 2018-03-28
WO2005097809A3 (en) 2006-02-16
HRP20110846T1 (hr) 2011-12-31
EP3385267A1 (en) 2018-10-10
IL219853A (en) 2015-05-31
US8283467B2 (en) 2012-10-09
PE20110075A1 (es) 2011-02-17
US20190112334A1 (en) 2019-04-18
PL1756121T3 (pl) 2012-02-29
EP3385267B1 (en) 2021-09-29

Similar Documents

Publication Publication Date Title
ES2531324T3 (es) Intermedio para producir un derivado de gamma-aminoácido bicíclico
ES2531396T3 (es) Proceso para preparar compuestos de piridinona
EA201170096A1 (ru) Замещенные производные пиримидона
CO5210949A1 (es) Trifluorometilalquilaminotriazolopirimidinas fungicidas
CR10499A (es) Profarmaco de compuesto de cinamida
CU23337B7 (es) Resolución de sal quiral
PE20131165A1 (es) Analogos de carba-nucleosidos sustituidos con 2'-fluoro para tratamiento antiviral
AR060873A1 (es) Derivados biciclicos como inhibidores de cetp
NO20071642L (no) N-Benzensulfonylsubstituerte anilino-pyrimidinanaloger
EA201490445A1 (ru) Циклопропанаминовое соединение
RU2011133749A (ru) Способ получения и выделения 2-ациламино-3-дифенилпропионовой кислоты
EA200500268A1 (ru) Производные диоксан-2-алкилкарбаматов, способ их получения и применение в терапии
EA200801607A1 (ru) Производные бензимидазолонкарбоновой кислоты
PE20110075A1 (es) Sintesis de compuestos de ester borico
RU2020108470A (ru) Аддитивная композиция для культуральной среды, аддитивное соединение для культуральной среды и способ культивирования клеток или тканей с использованием этой композиции и соединения
CR11578A (es) Derivados de oxadiazol activos e 1-fosfato de esfingosina
PE20120223A1 (es) Compuestos heterociclicos como inhibidores del transportador de glicina-1 (glyt-1)
AR059613A1 (es) Proceso para la preparacion de compuestos de dibenzotiazepina
BR0315112A (pt) Sal de adição ácido, e, processo para a preparação de um composto
BR112013005823B8 (pt) Compostos heterocíclicos para o tratamento ou prevenção de distúrbios causados pela neurotransmissão reduzida de serotonina, norefnefrina ou dopamina
RU2011105303A (ru) Способ получения n-алкил (алкил) акриламидов
AR047810A1 (es) Proceso quimico
PE20061421A1 (es) Compuestos de n-formil-hidroxilamina como inhibidores de peptidil-desformilasa
AR066430A1 (es) Proceso para preparar inhibidores de aromatasa y forma cristalina de exemestano
DK1970372T3 (da) Salte af 9-oxoacridin-10-eddikesyre med 1-alkylamino-1-deoxy-polyoler

Legal Events

Date Code Title Description
FA Abandonment or withdrawal
AE Restoration of lapsed or forfeited application
FC Refusal